

The Krembil Knowledge Gaps in Parkinson's Disease Symposium

Linking Pathogenesis with Disease Modification

Revision vs Reconstruction

April 24-26, 2019 | Marriott Downtown at Toronto Eaton Centre

CHALLENGE: How can disease modification in Parkinson's disease become a reality in the near future? If Parkinson's disease is not a single, homogeneous disorder, can advances in biomarkers and disease modification be **revised** to concentrate on commonalities of pathogenic mechanisms in large populations OR do they need to be **reconstructed** for application to smaller subgroups of patients, distinguished by well-defined molecular characteristics?

Steering Committee: Anthony E. Lang, Alfonso Fasano, Francesca Morgante, Alberto J. Espay, Andres M. Lozano, Lorraine Kalia, & Antonio Strafella

Program Highlights and Faculty

The Conceptual Challenges

- Anthony Lang
- Ron Postuma
- John Trojanowski
- Alberto Espay
- José Obeso
- Jon Stoessl

Big Data, Machine Learning, New Techniques, & Virtual Cohorts

- Caroline Williams-Gray
- Rudi Balling
- Todd Sherer
- Antonio Strafella

Disease Mechanisms

- Virginia Lee
- Dmitri Krainc
- Matt Farrer
- Adriano Aguzzi
- Lorraine Kalia
- James Surmeier
- David Standaert
- Patrik Brundin
- Andy Singleton

Experiences in Other Diseases in Neurology and Medicine

- George Perry
- Philippe Bedard
- Steven Rowe
- Francesca Morgante

Transplantation & Other Strategies

- Roger Barker
- Jeffrey Kordower
- Andres Lozano
- Alfonso Fasano

Trials - Biomarkers, Trial Designs, Consortiums, etc

- Jesse Cedarbaum
- Ken Marek

Trials - Trial Designs Including Lessons Learned

- Christopher Coffey
- Karl Kiebertz
- Howard Chertkow
- Michael Schwarzschild
- Warren Olanow
- Hubert Fernandez

www.gapsinmids.com

This program is endorsed by:

